{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:54:00Z","timestamp":1766516040697,"version":"3.48.0"},"reference-count":19,"publisher":"BMJ","issue":"6723","license":[{"start":{"date-parts":[[1990,2,24]],"date-time":"1990-02-24T00:00:00Z","timestamp":635817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"published-print":{"date-parts":[[1990,2,24]]},"abstract":"<jats:p>OBJECTIVE--To see whether combined treatment with oral tacrine (tetrahydroaminoacridine; THA) and lecithin improves the symptoms of patients with Alzheimer's disease. DESIGN--Multicentre double blind, placebo controlled, random order crossover trial with individual determination of maximum tolerated dosage and four month follow up. SETTING--Outpatient departments at six university neurological centres. PATIENTS--67 Outpatients (24 men, 43 women) aged 53-81 (mean 66 (SD 7.3)) selected according to the following criteria: probable Alzheimer's disease as defined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; absence of mood disorder; mini mental state score lower than 26; availability of a close relative able to complete questionnaires; and informed consent of the patient or his or her closest relative, or both. INTERVENTIONS--Mean of 114 mg tacrine or placebo daily plus 1200 mg lecithin daily given in three divided doses for one four week active treatment period and one four week control period without washout at crossover. MAIN OUTCOME MEASURES--Cognitive state as assessed by Folstein's mini mental state rating scale, behavioural state as assessed by the Stockton geriatric rating scale, and overall state as assessed with a visual analogue scale rated by both the relative and the physician. RESULTS--Compared with placebo tacrine did not improve either the mini mental state score (mean 14.9 (SD 7.3) v 14.8 (7.3)) or the Stockton geriatric score (28.2 (15.7) v 28.7 (17.8)), but a slight and statistically significant improvement occurred in the physician's score on the visual analogue scale (6.3 (10.2) v 11.6 (17.9)). Seven patients dropped out. Six patients were excluded because of acute hepatitis and one withdrew for personal reasons not related to treatment. Two other patients developed acute hepatitis at the end of the eight week crossover trial and another during the follow up study. Twenty patients complained of gastrointestinal side effects. CONCLUSIONS--Neither short term nor long term treatment with oral tacrine at dosages lower than 125 mg\/day improves the symptoms of Alzheimer's disease. Moreover, these dosages may induce hepatitis (nine of 67 patients in this series).<\/jats:p>","DOI":"10.1136\/bmj.300.6723.495","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T15:19:55Z","timestamp":1238685595000},"page":"495-499","source":"Crossref","is-referenced-by-count":118,"title":["Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine."],"prefix":"10.1136","volume":"300","author":[{"given":"G","family":"Chatellier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Lacomblez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1990,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJM198706183162512","article-title":"Oral tetrahydroaminoacridine in long-tcrm treatment of senile dementia, Alzheimer's type","volume":"316","author":"Pirrozzolo, F.J.; Baskin, D.S.; Swihart, A.A.; Appel, S.H.","year":"1987","unstructured":"Pirrozzolo FJ, Baskin DS, Swihart AA, Appel SH. Oral tetrahydroaminoacridine in long-tcrm treatment of senile dementia, Alzheimer's type. N EnglJ7 Med 1987;316:1603.","journal-title":"N EnglJ7 Med"},{"key":"ref_2","first-page":"172","article-title":"Tetrahvdroaminoacridine in Alzheimer's disease: a double-blind pilot study","volume":"3","author":"Lacomblez, L.; Chatellier, G.; Rapin, JR, LePoncin; M, Derouesnd; C.","year":"1989","unstructured":"Lacomblez L, Chatellier G, Rapin JR, LePoncin M, Derouesnd C. Tetrahvdroaminoacridine in Alzheimer's disease: a double-blind pilot study [Abstract]. Fundam Clin Pharmacol 1989;3:172.","journal-title":"Fundam Clin Pharmacol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-AD)RDA working group under the auspices of health and human services task force on Alzheimer's disease","volume":"34","author":"McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E.M.","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-AD)RDA working group under the auspices of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44.","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/archneur.1975.00490510088009","article-title":"Cerebral blood flow in dementia","volume":"32","author":"Hachinski, V.C.; Iliff, L.D.; Zilkha, E.","year":"1975","unstructured":"Hachinski VC, Iliff LD, Zilkha E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-7.","journal-title":"Arch Neurol"},{"key":"ref_5","article-title":"Diagnostic and statistical manual of mental dis(wrders, third edition","author":"Association, American Psychiatric","year":"1987","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental dis(wrders, third edition, revised. Washington, DC: Atuerican Psychiatric Association, 1987.","edition":"revised"},{"key":"ref_6","first-page":"189","article-title":"\"Mini tuental state.\" A practical method for grading the cognitive state of patients for clinicians","volume":"12","year":"1975","unstructured":"Folstein MF, Folstein SE, MicHugh PR. \"Mini tuental state.\" A practical method for grading the cognitive state of patients for clinicians. ] I'sychiatr Res 1975;12:189-98.","journal-title":"I'sychiatr Res"},{"key":"ref_7","first-page":"392403","article-title":"The Stockton geriatric rating scale.]","volume":"21","author":"Ieer, B.; Baker, J.A.","year":"1966","unstructured":"Ieer B, Baker JA. The Stockton geriatric rating scale.] Gerotiol 1966;21:392403."},{"key":"ref_8","first-page":"137","article-title":"Self assessment of cognitive deficits","volume-title":"in geriatoic psychopharmacology","author":"DM, Mac Nair; RJ, Kahn","year":"1983","unstructured":"Mac Nair DM, Kahn RJ. Self assessment of cognitive deficits. In: Crook r, Ferris S, Bartus R, eds. Assessment in geriatoic psychopharmacology. New Canaan, Conn: Marc Powlev, 1983:137-44."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.3317822","article-title":"Alzheimer's drug trial put on hold","volume":"238","author":"Marx, J.L.","year":"1987","unstructured":"Marx JL. Alzheimer's drug trial put on hold. Science 1987;238:1041-2.","journal-title":"Science"},{"key":"ref_10","first-page":"7","article-title":"The two-period cross-over clinical trial. Br.7 Clin","volume":"8","author":"Hills, M.; Armitage, P.","year":"1979","unstructured":"Hills M, Armitage P. The two-period cross-over clinical trial. Br.7 Clin Pharmacol 1979;8:7-20.","journal-title":"Pharmacol"},{"key":"ref_11","article-title":"SAS user's guide: statistics, version 5","author":"SAS Institute","year":"1985","unstructured":"SAS Institute. SAS user's guide: statistics, version 5. Cars, NC: SAS Institute, 1985."},{"key":"ref_12","first-page":"275","article-title":"Modest facilitation of memorv in dementia with combined lecithin and anticholincsterase treatmetit","volume":"17","author":"Kaye, W.H.; Sitaram, N.; Weingartner, H.","year":"1982","unstructured":"Kaye WH, Sitaram N, Weingartner H. Modest facilitation of memorv in dementia with combined lecithin and anticholincsterase treatmetit. Riol Psvchiatry 1982;17:275-80.","journal-title":"Riol Psvchiatry"},{"key":"ref_13","first-page":"237","article-title":"TetrahNdroaminoacridine and lecithin in Alzheimer's disease","volume-title":"Current research in Alzhetmer therapy","author":"Gauthier, S.; Masson, H.; Gauthier, L.","year":"1988","unstructured":"Gauthier S, Masson H, Gauthier L, et al. TetrahNdroaminoacridine and lecithin in Alzheimer's disease. In: Giacobini E, Becker R, eds. Current research in Alzhetmer therapy. London: Taylor and Francis, 1988:237-45."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/jnnp.48.8.736","article-title":"A double-blind placebocontrolled trial of high-dose lecithin in Alzheimer's disease","volume":"48","author":"Little, A.; Levy, R.; Chuaqui-Kidd, P.; Hand, D.","year":"1985","unstructured":"Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind placebocontrolled trial of high-dose lecithin in Alzheimer's disease. J Neuroil Neurosurg Psychiatry 1985;48:736-42.","journal-title":"J Neuroil Neurosurg Psychiatry"},{"key":"ref_15","first-page":"1457","article-title":"Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia","volume":"ii:","author":"Perry, E.K.; Tomlinson, B.E.; Blessed, G.","year":"1978","unstructured":"Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia. BrM_d7 1978;ii: 1457-9.","journal-title":"BrM_d7"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJM198708133170706","article-title":"Statistical problems in the reporting of clinical trials. A sursey of three medical journals","volume":"317","author":"Pocock, S.J.; Hughes, A.I.D.; Lee, R.J.","year":"1987","unstructured":"Pocock SJ, Hughes AID, Lee RJ. Statistical problems in the reporting of clinical trials. A sursey of three medical journals. N EnglJ Med 1987;317: 426-32.","journal-title":"N EnglJ Med"},{"key":"ref_17","first-page":"219","article-title":"Intraventricular bethanechol infusion for Alzheimer's disease: results of a double-blind and cscalating-dose trial. Neurologs'","volume":"38","author":"Penn, R.D.; Martin, E.M.; Wilson, R.S.; Fox, J.H.; Savoy, S.M.","year":"1988","unstructured":"Penn RD, Martin EM, Wilson RS, Fox JH, Savoy SM. Intraventricular bethanechol infusion for Alzheimer's disease: results of a double-blind and cscalating-dose trial. Neurologs' 1988;38:219-22."},{"key":"ref_18","first-page":"887","article-title":"Hepatotoxicity of tetrahydroacridine","volume":"i:","author":"Ames, D.J.; Bhatal, P.S.; Davies, B.M.; Fraser, J.R.E.","year":"1988","unstructured":"Ames DJ, Bhatal PS, Davies BM, Fraser JRE. Hepatotoxicity of tetrahydroacridine. Lancet 1988;i:887.","journal-title":"Lancet"},{"key":"ref_19","first-page":"1305","article-title":"Cholinergic side-effects of tetrahydroaminoacridine","volume":"ii:","author":"Wilcock, G.K.; Surmon, D.; Forsyth, D.; Morgan, R.","year":"1988","unstructured":"Wilcock GK, Surmon D, Forsyth D, Morgan R. Cholinergic side-effects of tetrahydroaminoacridine. Lancet 1988;ii: 1305.","journal-title":"Lancet"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.300.6723.495","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.300.6723.495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:42:55Z","timestamp":1765489375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.300.6723.495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,2,24]]},"references-count":19,"journal-issue":{"issue":"6723","published-online":{"date-parts":[[1990,2,24]]},"published-print":{"date-parts":[[1990,2,24]]}},"alternative-id":["10.1136\/bmj.300.6723.495"],"URL":"https:\/\/doi.org\/10.1136\/bmj.300.6723.495","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"type":"print","value":"0959-8138"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[1990,2,24]]}}}